Two Sigma Securities LLC Sells 21,104 Shares of Baxter International Inc. $BAX

Two Sigma Securities LLC trimmed its position in shares of Baxter International Inc. (NYSE:BAX) by 67.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,960 shares of the medical instruments supplier’s stock after selling 21,104 shares during the period. Two Sigma Securities LLC’s holdings in Baxter International were worth $212,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Imprint Wealth LLC bought a new stake in shares of Baxter International during the 3rd quarter worth approximately $27,000. Jones Financial Companies Lllp bought a new stake in Baxter International during the second quarter worth $26,000. Basepoint Wealth LLC acquired a new stake in shares of Baxter International in the 4th quarter valued at $26,000. MUFG Securities EMEA plc bought a new position in shares of Baxter International in the 2nd quarter valued at $46,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Baxter International in the 4th quarter valued at $46,000. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Price Performance

BAX stock opened at $25.81 on Friday. The company has a fifty day moving average price of $24.73 and a 200-day moving average price of $20.72. The company has a market capitalization of $13.34 billion, a P/E ratio of -12.47, a PEG ratio of 3.87 and a beta of 0.60. Baxter International Inc. has a 52-week low of $15.73 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.32 and a current ratio of 1.95.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. The company had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. Baxter International’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 earnings per share. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, equities analysts expect that Baxter International Inc. will post 2.04 EPS for the current year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Friday, August 28th will be given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th. Baxter International’s payout ratio is -1.93%.

Analysts Set New Price Targets

Several analysts recently weighed in on BAX shares. Citigroup upgraded Baxter International from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $17.00 to $28.00 in a research report on Friday, July 31st. Weiss Ratings raised shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. TD Cowen lifted their price target on shares of Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a report on Monday, July 27th. The Goldman Sachs Group increased their price objective on shares of Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Finally, Wells Fargo & Company increased their price target on Baxter International from $19.00 to $23.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $22.45.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.